This is precisely where Tecan Trading envisions the future of automation. With nearly twenty years in the field, Hal Wehrenberg, Vice President of Digital Transformation at Tecan, has played a pivotal ...
New SELECT trial insights suggest semaglutide’s cardiovascular protection goes beyond weight loss, pointing to broader cardiometabolic mechanisms and reshaping how clinicians may view GLP-1 therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results